Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer

Published:2002-07 Issue:6 Volume:13 Page:655-662
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:Anti-Cancer Drugs

Author:

Yeo Winnie,Mok Tony SK,Tse Kin K,Kwan Wing H,Lam Kwok C,Ho Wing M,Chiu Samuel KW,Chan Anthony TC,Leung Thomas WT,Mo Frankie KF,Johnson Philip J

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference34 articles.

1. Docetaxel (Taxotere®), a review of preclinical and clinical experience. Part II

2. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

3. Relationships between the structure of taxol analogs and their antimitotic activity

4. Motility and invasive potency of murine T-lymphoma cells: effect of microtubule inhibitors.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers;Advances in Therapy;2021-10-26

2. Fever and breast cancer: A critical review of the literature and possible underlying mechanisms;Breast Disease;2021-07-15

3. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment;Annals of Oncology;2016-12

4. Protective Effect of Astragalus polysaccharides on Liver Injury Induced by Several Different Chemotherapeutics in Mice;Asian Pacific Journal of Cancer Prevention;2015-01-06

5. Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer;International Journal of Breast Cancer;2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3